LPTX
Leap Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 0
Bearish signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LPTX
Leap Therapeutics, Inc.
A biotechnology company that develops targeted and immuno-oncology therapeutics
47 Thorndike Street, Suite B1-1, Cambridge, MA 02141
--
Leap Therapeutics, Inc., was originally incorporated as Dekkun Corporation on January 3, 2011, a Delaware corporation. The company is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat cancer patients by inhibiting basic tumor-promoting pathways, targeting cancer-specific cell surface molecules and using the immune system to attack cancer cells. Their strategy is to identify, acquire and develop molecules that will rapidly translate into high-impact treatments that produce long-lasting clinical benefits and improve patient outcomes. Their main clinical stage project is DKN-01, a monoclonal antibody that inhibits dickkopf-associated protein 1 (" DKK1 "). They are currently investigating the application of DKN-01 in patients with esophageal, gastric, gynecological or colorectal cancer in several ongoing clinical trials. Their second clinical stage project is FL -301, a monoclonal antibody against cells expressing Claudin 18.2 on the cell surface. They also have two preclinical antibody programs, FL-302 and FL-501.
Company Financials
EPS
LPTX has released its 2025 Q2 earnings. EPS was reported at -0.4, versus the expected -0.29, missing expectations. The chart below visualizes how LPTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
